Next-generation, genome sequencing-based biomarkers: Concerns and challenges for medical practice

Biomarkers in Medicine

Volumn 4, Issue 4, 2010, Pages 583-586

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

biomarker; genome sequencing; genome wide association studies

Indexed keywords

BIOLOGICAL MARKER;

CANCER RISK; EDITORIAL; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL PRACTICE; MULTIGENE FAMILY; PHARMACOGENETICS; PROGNOSIS; PROTEOMICS; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRACTICE MANAGEMENT, MEDICAL; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 77955596399     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.70     Document Type: Editorial

References (37)

1. Lin K, Lipsitz R, Miller T, Janakiraman S; US Preventive Services Task Force: Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149(3), 192-199 (2008)
2. Edge SE, Byrd DR, Carducci MA, Compton CA (Eds): AJCC Cancer Staging Manual (7th Edition). Springer, NY, USA (2009)
3. Roederer MW: Cytochrome P450 enzymes and genotype-guided drug therapy. Curr. Opin. Mol. Ther. 11(6), 632-640 (2009)
4. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004)
5. van de Vijver MJ, He YD, vant Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002)
6. OShaughnessy JA: Molecular signatures predict outcomes of breast cancer. N. Engl. J. Med. 355(6), 615-617 (2006)
7. Huang CC, Bredel M: Use of gene signatures to improve risk estimation in cancer. JAMA 299(13), 1605-1606 (2008)
8. Goldstein DB: 2020 visions. Personalized medicine. Nature 463(7277), 26-32 (2010)
9. Roukos DH: Genome-wide association studies: how predictable is a persons cancer risk? Expert Rev. Anticancer Ther. 9(4), 389-392 (2009)
10. Kathiresan S, Melander O, Anevski D et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358(12), 1240-1249 (2008)
11. Wacholder S, Hartge P, Prentice R et al.: Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010)
12. No authors listed. Human genome at ten: the sequence explosion. Nature 464(7289), 670-671 (2010)
13. No authors listed. The human genome at ten. Nature 464(7289), 649-650 (2010)
14. Check Hayden E: Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010)
15. Ledford H: Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010)
16. Collins F: Has the revolution arrived? Nature 464(7289), 674-675 (2010)
17. Venter JC: Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
18. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458(7239), 719-724 (2009)
19. Pleasance ED, Stephens PJ, OMeara S et al.: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010)
20. Pleasance ED, Cheetham RK, Stephens PJ et al.: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196
21. Stephens PJ, McBride DJ, Lin ML et al.: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009)
22. Beroukhim R, Mermel CH, Porter D et al.: The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010)
23. Ding L, Ellis MJ, Li S et al.: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7 291), 999-1005 (2010)
24. Jones S, Zhang X, Parsons DW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008)
25. Roukos DH: Novel clinico-genome network modeling for revolutionizing genotype- phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010)
26. Rockman MV: Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008)
27. Roukos DH: Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010)
28. Roukos DH: Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010)
29. Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009)
30. Weinberg R: Point: hypotheses first. Nature 464(7289), 678 (2010)
31. Roukos DH, Ziogas D: From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther. 10(2), 123-128 (2010)
32. Roukos DH: Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann. Surg. 249(6), 1067-1068 (2009)
33. Ziogas D, Roukos DH: Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009)
34. Roukos DH: Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn. 9(3), 227-229 (2009)
35. Roukos DH: Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J. Clin. Oncol. 28(17), E279-E280 (2010)
36. Roukos DH: Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010)
37. Roukos DH: Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol. 16(3), 772-773 (2009)